Cardiovascular and Cerebrovascular Events in Temporal Relationship to Intravenous Glucocorticoid Pulse Therapy in Patients with Severe Endocrine Ophthalmopathy

Abstract

ThyroidVol. 19, No. 12 Letters to the EditorCardiovascular and Cerebrovascular Events in Temporal Relationship to Intravenous Glucocorticoid Pulse Therapy in Patients with Severe Endocrine OphthalmopathyMaria E. Lendorf, Åse Krogh Rasmussen, Hans C. Fledelius, and Ulla Feldt-RasmussenMaria E. LendorfDepartment of Ophthalmology, National University Hospital, Rigshospitalet, Copenhagen, Denmark.Search for more papers by this author, Åse Krogh RasmussenDepartment of Medical Endocrinology, National University Hospital, Rigshospitalet, Copenhagen, Denmark.Search for more papers by this author, Hans C. FledeliusDepartment of Ophthalmology, National University Hospital, Rigshospitalet, Copenhagen, Denmark.Search for more papers by this author, and Ulla Feldt-RasmussenDepartment of Medical Endocrinology, National University Hospital, Rigshospitalet, Copenhagen, Denmark.Search for more papers by this authorPublished Online:14 Dec 2009https://doi.org/10.1089/thy.2009.0069AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article"Cardiovascular and Cerebrovascular Events in Temporal Relationship to Intravenous Glucocorticoid Pulse Therapy in Patients with Severe Endocrine Ophthalmopathy." , 19(12), pp. 1431–1432FiguresReferencesRelatedDetailsCited byDrug safety in thyroid eye disease – a systematic review15 August 2022 | Expert Opinion on Drug Safety, Vol. 21, No. 7Safety of Intravenous Methylprednisolone in Refractory and Severe Pediatric Uveitis1 May 2022 | Clinical Ophthalmology, Vol. Volume 16Comparison of efficacy and safety of parenteral versus parenteral and oral glucocorticoid therapy in Graves’ orbitopathy2 August 2020 | International Journal of Clinical Practice, Vol. 74, No. 11Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application14 December 2020 | Therapeutic Advances in Endocrinology and Metabolism, Vol. 11Acute bilateral cerebral infarction in the presence of neuromyelitis optica spectrum disorder2 October 2020 | Medicine, Vol. 99, No. 40Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves’ orbitopathy23 December 2019 | Thyroid Research, Vol. 12, No. 1Methotrexate as an Adjuvant in Severe Thyroid Eye Disease: Does It Really Work as a Steroid-Sparing Agent?Ophthalmic Plastic & Reconstructive Surgery, Vol. 35, No. 4Endocrine orbitopathy: the present view of a clinical endocrinologistVnitřní lékařství, Vol. 63, No. 10Retracted : Efficacy and safety of mycophenolate mofetil in patients with active moderate‐to‐severe Graves’ orbitopathy7 September 2016 | Clinical Endocrinology, Vol. 86, No. 2Management of Dysthyroid Optic Neuropathy17 December 2016THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves’ orbitopathyEuropean Journal of Endocrinology, Vol. 175, No. 3Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves’ orbitopathy10 January 2015 | Journal of Endocrinological Investigation, Vol. 38, No. 2Safety Profile and Effects of Pulsed Methylprednisolone on Vital Signs in Thyroid Eye DiseaseInternational Journal of Endocrinology, Vol. 2015Thyroid Eye Disease: A Comprehensive ReviewMeta-analysis of methylprednisolone pulse therapy for Graves' ophthalmopathy4 April 2014 | Clinical & Experimental Ophthalmology, Vol. 42, No. 8A Prospective, Randomized Trial of Intravenous Glucocorticoids Therapy With Different Protocols for Patients With Graves' OphthalmopathyThe Journal of Clinical Endocrinology & Metabolism, Vol. 99, No. 6Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' OrbitopathyThe Journal of Clinical Endocrinology & Metabolism, Vol. 97, No. 12Treatment of mild, moderate-to-severe and very severe Graves’ orbitopathyBest Practice & Research Clinical Endocrinology & Metabolism, Vol. 26, No. 3Treatment options for Graves' orbitopathy9 March 2012 | Expert Opinion on Pharmacotherapy, Vol. 13, No. 6Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid AssociationEuropean Journal of Endocrinology, Vol. 166, No. 2Corticotrophins, corticosteroids, and prostaglandins Volume 19Issue 12Dec 2009 InformationCopyright 2009, Mary Ann Liebert, Inc.To cite this article:Maria E. Lendorf, Åse Krogh Rasmussen, Hans C. Fledelius, and Ulla Feldt-Rasmussen.Cardiovascular and Cerebrovascular Events in Temporal Relationship to Intravenous Glucocorticoid Pulse Therapy in Patients with Severe Endocrine Ophthalmopathy.Thyroid.Dec 2009.1431-1432.http://doi.org/10.1089/thy.2009.0069Published in Volume: 19 Issue 12: December 14, 2009Online Ahead of Print:November 7, 2009PDF download